• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, ASHITAKA CAPIOX HEMOCONCENTRATOR; DIALYSATE SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, ASHITAKA CAPIOX HEMOCONCENTRATOR; DIALYSATE SYSTEM Back to Search Results
Catalog Number CX*HC11L
Device Problem Device Inoperable (1663)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 06/28/2017
Event Type  malfunction  
Manufacturer Narrative
The actual device was returned to the manufacturing facility for evaluation.The investigation is currently ongoing.A follow up report will be submitted once the investigation is complete.For this reason (b)(4) was used in the conclusions section of evaluation codes.A review of the device history record and shipping inspection record of the involved product code/lot number combination was conducted with no relevant findings.A search of the complaint file found no other report with the involved product code/lot# combination.(b)(4).All available information has been placed on file in quality assurance at the manufacturing facility for appropriate tracking, trending and follow-up.
 
Event Description
The user facility reported an issue with the capiox hemoconcentrator device during a procedure.Follow up communication with the user facility confirmed the following information: it was reported the filter function did not work; and the perfusionist immediately changed the defect sample to a new one.
 
Manufacturer Narrative
This report is being submitted as follow up number 1 to provide the actual device evaluation results.The actual device was returned to the manufacturing facility for evaluation.Visual inspection found no anomalies in the appearance.The actual device was rinsed dried and subjected to another visual inspection.There were no anomalies in the appearance.The actual device was circulated with bovine blood while ultra-filtrating performance and the pressure drop were determined.They results were confirmed to meet manufacturing specifications.There is no evidence that this event was related to a device defect or malfunction.The actual sample after having been rinsed and dried was verified to have normal performance in the pressure drop and the ultra-filtrating.While the exact cause of the reported event cannot be definitively determined based on the available information, it is likely the dehydrating performance of the actual device was deteriorated due to the fibers being clogged.As a cause of the fibers being clogged, the below factors can be inferred experientially.Due to some factor(s), the flow rate of blood going into the actual device was decreased.By this, blood was concentrated excessively and clogged in the fibers.Blood concentrated due to administration of packed red blood cell or inflow of dehydrated blood was further concentrated when it flowed into the actual device and became clogged in the fibers.The device labeling does address the potential for such an event in the instructions-for-use (ifu) with statements such as the following: the capiox hemoconcentrator is designed to operate at flow rates within the range of 100 to 500 ml/min during ultrafiltration.Do not use blood flow rates outside this range.Less than 100ml/min blood flow may cause blood coagulation in the device.Stop using the hemoconcentrator if blood leakage, clotting or any other problem is observed.Replace it with a new one.Do not exceed 50% hematocrit at the blood outlet during ultrafiltration.Do not stop blood flow during extracorporeal circulation as it may cause clotting in the system.A blood flow of at least 50ml/min is recommended even if ultrafiltration is stopped by clamping the filtrate line.All available information has been placed on file in quality assurance at the manufacturing facility for appropriate tracking, trending and follow-up.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CAPIOX HEMOCONCENTRATOR
Type of Device
DIALYSATE SYSTEM
Manufacturer (Section D)
TERUMO CORPORATION, ASHITAKA
150 maimaigi-cho
fujinomiya city, shizuoka 418
TW  418
Manufacturer (Section G)
TERUMO CORPORATION, ASHITAKA
reg. no. 9681834
150 maimaigi-cho
fujinomiya city, shizuoka 418
JA   418
Manufacturer Contact
terry callahan
reg. no. 2243441
2101 cottontail ln.
somerset, NJ 08873
8002837866
MDR Report Key6735712
MDR Text Key80787808
Report Number9681834-2017-00147
Device Sequence Number1
Product Code KDI
UDI-Device Identifier04987350738417
UDI-Public(01)04987350738417(17)200131(10)170213
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K973516
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 07/24/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/24/2017
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2020
Device Catalogue NumberCX*HC11L
Device Lot Number170213
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer07/21/2017
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Date Manufacturer Received07/21/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured02/13/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-